Trial Profile
A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms STELLA
- Sponsors mAbxience
- 08 Jun 2021 Results assessing the multiple imputation analysis, clinical equivalence and biosimilarity of MB02 with EU-bevacizumab demonstrated by the efficacy data, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 29 Apr 2021 Results published in the BioDrugs
- 07 Sep 2020 Status changed from active, no longer recruiting to completed.